Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 1201

1.

Genetic hallmarks of recurrent/metastatic adenoid cystic carcinoma.

Ho AS, Ochoa A, Jayakumaran G, Zehir A, Valero Mayor C, Tepe J, Makarov V, Dalin MG, He J, Bailey M, Montesion M, Ross JS, Miller VA, Chan L, Ganly I, Dogan S, Katabi N, Tsipouras P, Ha P, Agrawal N, Solit DB, Futreal PA, El Naggar AK, Reis-Filho JS, Weigelt B, Ho AL, Schultz N, Chan TA, Morris LG.

J Clin Invest. 2019 Sep 4. pii: 128227. doi: 10.1172/JCI128227. [Epub ahead of print]

2.

Evidence Supporting US Food and Drug Administration Drug Safety Communications.

Ross JS.

JAMA Intern Med. 2019 Sep 3. doi: 10.1001/jamainternmed.2019.3065. [Epub ahead of print] No abstract available.

PMID:
31479098
3.

A Novel Next-Generation Sequencing Approach to Detecting Microsatellite Instability (MSI) and Pan-Tumor Characterization of One Thousand MSI-High Cases in 67,000 Patient Samples.

Trabucco SE, Gowen K, Maund SL, Sanford E, Fabrizio DA, Hall MJ, Yakirevich E, Gregg JP, Stephens PJ, Frampton GM, Hegde PS, Miller VA, Ross JS, Hartmaier RJ, Huang SA, Sun JX.

J Mol Diagn. 2019 Aug 21. pii: S1525-1578(19)30358-7. doi: 10.1016/j.jmoldx.2019.06.011. [Epub ahead of print]

4.

Comprehensive characterization of RAS mutations in colon and rectal cancers in old and young patients.

Serebriiskii IG, Connelly C, Frampton G, Newberg J, Cooke M, Miller V, Ali S, Ross JS, Handorf E, Arora S, Lieu C, Golemis EA, Meyer JE.

Nat Commun. 2019 Aug 19;10(1):3722. doi: 10.1038/s41467-019-11530-0.

5.

Adoption of New Glucose-Lowering Medications in the U.S. - the case of SGLT2 inhibitors: Nationwide cohort study.

McCoy RG, Dykhoff HJ, Sangaralingham LR, Ross JS, Karaca-Mandic P, Montori VM, Shah N.

Diabetes Technol Ther. 2019 Aug 16. doi: 10.1089/dia.2019.0213. [Epub ahead of print]

PMID:
31418588
6.

Comprehensive Genomic Profiling of Adult Renal Sarcomas Provides Insight into Disease Biology and Opportunities for Targeted Therapies.

Yakirevich E, Madison R, Fridman E, Mangray S, Carneiro BA, Lu S, Cooke M, Bratslavsky G, Webster J, Ross JS, Ali SM.

Eur Urol Oncol. 2019 Apr 22. pii: S2588-9311(19)30044-6. doi: 10.1016/j.euo.2019.04.002. [Epub ahead of print]

PMID:
31412008
7.

Medicare Part D Spending on Single-Enantiomer Drugs Versus Their Racemic Precursors.

Egilman AC, Zhang AD, Wallach JD, Ross JS.

Ann Intern Med. 2019 Aug 13. doi: 10.7326/M19-1085. [Epub ahead of print] No abstract available.

PMID:
31404926
8.

MET Genomic Alterations in Head and Neck Squamous Cell Carcinoma (HNSCC): Rapid Response to Crizotinib in a Patient with HNSCC with a Novel MET R1004G Mutation.

Chu LP, Franck D, Parachoniak CA, Gregg JP, Moore MG, Farwell DG, Rao S, Heilmann AM, Erlich RL, Ross JS, Miller VA, Ali S, Riess JW.

Oncologist. 2019 Aug 7. pii: theoncologist.2019-0230. doi: 10.1634/theoncologist.2019-0230. [Epub ahead of print]

PMID:
31391294
9.

Rates of Physician Coprescribing of Opioids and Benzodiazepines After the Release of the Centers for Disease Control and Prevention Guidelines in 2016.

Jeffery MM, Hooten WM, Jena AB, Ross JS, Shah ND, Karaca-Mandic P.

JAMA Netw Open. 2019 Aug 2;2(8):e198325. doi: 10.1001/jamanetworkopen.2019.8325.

10.

Improving the Prognostic Ability for Personalized Therapeutic Approaches in Nonseminomatous Germ Cell Tumors.

Necchi A, Ross JS, Spiess PE.

J Clin Oncol. 2019 Sep 10;37(26):2314-2316. doi: 10.1200/JCO.19.01672. Epub 2019 Jul 30. No abstract available.

PMID:
31361537
11.

Medicare Spending on Drugs and Biologics Not Recommended for Coverage by International Health Technology Assessment Agencies.

Egilman AC, Wallach JD, Dhruva SS, Gonsalves GS, Ross JS.

J Gen Intern Med. 2019 Jul 16. doi: 10.1007/s11606-019-05149-6. [Epub ahead of print] No abstract available.

PMID:
31313117
12.

The Bleeding Edge: Documenting Innovation and Injury in the Medical Device Industry.

Pendyal A, Ross JS.

JAMA. 2019 Jul 16;322(3):190-192. doi: 10.1001/jama.2019.8147. No abstract available.

PMID:
31310276
13.

Association Between Food and Drug Administration Advisory Committee Recommendations and Agency Actions, 2008-2015.

Zhang AD, Schwartz JL, Ross JS.

Milbank Q. 2019 Sep;97(3):796-819. doi: 10.1111/1468-0009.12403. Epub 2019 Jul 14.

PMID:
31304643
14.

Pan-Cancer Analysis of CDK12 Loss-of-Function Alterations and Their Association with the Focal Tandem-Duplicator Phenotype.

Sokol ES, Pavlick D, Frampton GM, Ross JS, Miller VA, Ali SM, Lotan TL, Pardoll DM, Chung JH, Antonarakis ES.

Oncologist. 2019 Jul 10. pii: theoncologist.2019-0214. doi: 10.1634/theoncologist.2019-0214. [Epub ahead of print]

PMID:
31292271
16.

Clinical Trial Evidence for the Real World.

Ross JS, Covinsky K.

JAMA Intern Med. 2019 Jul 8. doi: 10.1001/jamainternmed.2019.1500. [Epub ahead of print] No abstract available.

PMID:
31282933
17.

Association Between Industry Payments to Physicians and Gabapentinoid Prescribing.

Rhee TG, Ross JS.

JAMA Intern Med. 2019 Jul 8. doi: 10.1001/jamainternmed.2019.1082. [Epub ahead of print] No abstract available.

PMID:
31282922
18.

Prevalence of established and emerging biomarkers of immune checkpoint inhibitor response in advanced hepatocellular carcinoma.

Ang C, Klempner SJ, Ali SM, Madison R, Ross JS, Severson EA, Fabrizio D, Goodman A, Kurzrock R, Suh J, Millis SZ.

Oncotarget. 2019 Jun 18;10(40):4018-4025. doi: 10.18632/oncotarget.26998. eCollection 2019 Jun 18.

19.

FGFR2-Altered Gastroesophageal Adenocarcinomas Are an Uncommon Clinicopathologic Entity with a Distinct Genomic Landscape.

Klempner SJ, Madison R, Pujara V, Ross JS, Miller VA, Ali SM, Schrock AB, Kim ST, Maron SB, Dayyani F, Catenacci DVT, Lee J, Chao J.

Oncologist. 2019 Jun 27. pii: theoncologist.2019-0121. doi: 10.1634/theoncologist.2019-0121. [Epub ahead of print]

PMID:
31249137
20.

Clinical and Immunological Implications of Frameshift Mutations in Lung Cancer.

Chae YK, Viveiros P, Lopes G, Sukhadia B, Sheikh MM, Saravia D, Florou V, Sokol ES, Frampton GM, Chalmers ZR, Ali SM, Ross JS, Chang S, Wang S, Chiec L, Rahbari A, Mohindra N, Villaflor V, Shin SH, Oh M, Anker J, Park LC, Wang V, Chuang J, Park W.

J Thorac Oncol. 2019 Jun 22. pii: S1556-0864(19)30496-4. doi: 10.1016/j.jtho.2019.06.016. [Epub ahead of print]

PMID:
31238177
21.

Prospective Comprehensive Genomic Profiling of Primary and Metastatic Prostate Tumors.

Chung JH, Dewal N, Sokol E, Mathew P, Whitehead R, Millis SZ, Frampton GM, Bratslavsky G, Pal SK, Lee RJ, Necchi A, Gregg JP, Lara P Jr, Antonarakis ES, Miller VA, Ross JS, Ali SM, Agarwal N.

JCO Precis Oncol. 2019;3. doi: 10.1200/PO.18.00283. Epub 2019 May 10.

22.

Postmarketing commitments for novel drugs and biologics approved by the US Food and Drug Administration: a cross-sectional analysis.

Wallach JD, Luxkaranayagam AT, Dhruva SS, Miller JE, Ross JS.

BMC Med. 2019 Jun 17;17(1):117. doi: 10.1186/s12916-019-1344-3.

23.

SMARCA4 inactivation defines a subset of undifferentiated uterine sarcomas with rhabdoid and small cell features and germline mutation association.

Lin DI, Allen JM, Hecht JL, Killian JK, Ngo NT, Edgerly C, Severson EA, Ali SM, Erlich RL, Ramkissoon SH, Vergilio JA, Ross JS, Elvin JA.

Mod Pathol. 2019 Jun 12. doi: 10.1038/s41379-019-0303-z. [Epub ahead of print]

PMID:
31190001
24.

Noninferiority Designed Cardiovascular Trials in Highest-Impact Journals.

Bikdeli B, Welsh JW, Akram Y, Punnanithinont N, Lee I, Desai NR, Kaul S, Stone GW, Ross JS, Krumholz HM.

Circulation. 2019 Jul 30;140(5):379-389. doi: 10.1161/CIRCULATIONAHA.119.040214. Epub 2019 Jun 10.

PMID:
31177811
25.

Genomic Features of Metastatic Testicular Sex Cord Stromal Tumors.

Necchi A, Bratslavsky G, Shapiro O, Elvin JA, Vergilio JA, Killian JK, Ngo N, Ramkissoon S, Severson E, Hemmerich AC, Ali SM, Chung JH, Reddy P, Miller VA, Schrock AB, Gay LM, Ross JS, Jacob JM.

Eur Urol Focus. 2019 May 27. pii: S2405-4569(19)30149-X. doi: 10.1016/j.euf.2019.05.012. [Epub ahead of print]

PMID:
31147264
26.

Adverse Effects of Pharmacologic Treatments of Major Depression in Older Adults.

Sobieraj DM, Martinez BK, Hernandez AV, Coleman CI, Ross JS, Berg KM, Steffens DC, Baker WL.

J Am Geriatr Soc. 2019 Aug;67(8):1571-1581. doi: 10.1111/jgs.15966. Epub 2019 May 29.

PMID:
31140587
27.

Analysis of Postapproval Clinical Trials of Therapeutics Approved by the US Food and Drug Administration Without Clinical Postmarketing Requirements or Commitments.

Skydel JJ, Luxkaranayagam AT, Dhruva SS, Ross JS, Wallach JD.

JAMA Netw Open. 2019 May 3;2(5):e193410. doi: 10.1001/jamanetworkopen.2019.3410.

28.

Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for Therapy.

Parikh AR, He Y, Hong TS, Corcoran RB, Clark JW, Ryan DP, Zou L, Ting DT, Catenacci DV, Chao J, Fakih M, Klempner SJ, Ross JS, Frampton GM, Miller VA, Ali SM, Schrock AB.

Oncologist. 2019 Apr 30. pii: theoncologist.2019-0034. doi: 10.1634/theoncologist.2019-0034. [Epub ahead of print]

PMID:
31040255
29.

Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer.

Schrock AB, Ouyang C, Sandhu J, Sokol E, Jin D, Ross JS, Miller VA, Lim D, Amanam I, Chao J, Catenacci D, Cho M, Braiteh F, Klempner SJ, Ali SM, Fakih M.

Ann Oncol. 2019 Jul 1;30(7):1096-1103. doi: 10.1093/annonc/mdz134.

PMID:
31038663
30.

Association of Pharmaceutical Manufacturer Payments to Physicians and Prescribing Dosage of Opioids.

Fleischman W, Agrawal S, Gross CP, Ross JS.

J Gen Intern Med. 2019 Jul;34(7):1074-1076. doi: 10.1007/s11606-019-04897-9. No abstract available.

PMID:
31011967
31.

Molecular profiling of cancer patients enables personalized combination therapy: the I-PREDICT study.

Sicklick JK, Kato S, Okamura R, Schwaederle M, Hahn ME, Williams CB, De P, Krie A, Piccioni DE, Miller VA, Ross JS, Benson A, Webster J, Stephens PJ, Lee JJ, Fanta PT, Lippman SM, Leyland-Jones B, Kurzrock R.

Nat Med. 2019 May;25(5):744-750. doi: 10.1038/s41591-019-0407-5. Epub 2019 Apr 22.

PMID:
31011206
32.

Adverse Effects of Pharmacologic Treatments of Major Depression in Older Adults [Internet].

Sobieraj DM, Baker WL, Martinez BK, Hernandez AV, Coleman CI, Ross JS, Berg KM, Steffens DC.

Rockville (MD): Agency for Healthcare Research and Quality (US); 2019 Mar.

33.

Risk of Readmission After Discharge From Skilled Nursing Facilities Following Heart Failure Hospitalization: A Retrospective Cohort Study.

Weerahandi H, Li L, Bao H, Herrin J, Dharmarajan K, Ross JS, Kim KL, Jones S, Horwitz LI.

J Am Med Dir Assoc. 2019 Apr;20(4):432-437. doi: 10.1016/j.jamda.2019.01.135.

PMID:
30954133
34.

Association Between Insurance Status and Access to Hospital Care in Emergency Department Disposition.

Venkatesh AK, Chou SC, Li SX, Choi J, Ross JS, D'Onofrio G, Krumholz HM, Dharmarajan K.

JAMA Intern Med. 2019 May 1;179(5):686-693. doi: 10.1001/jamainternmed.2019.0037.

PMID:
30933243
35.

Kept in the dark: Scotland rejects "sunshine" legislation.

Ross JS.

BMJ. 2019 Mar 29;364:l1379. doi: 10.1136/bmj.l1379. No abstract available.

PMID:
30926587
36.

Association of a Risk Evaluation and Mitigation Strategy Program With Transmucosal Fentanyl Prescribing.

Fleischman W, Auth D, Shah ND, Agrawal S, Ross JS.

JAMA Netw Open. 2019 Mar 1;2(3):e191340. doi: 10.1001/jamanetworkopen.2019.1340.

37.

Submissions from the SPRINT Data Analysis Challenge on clinical risk prediction: a cross-sectional evaluation.

Jackevicius CA, An J, Ko DT, Ross JS, Angraal S, Wallach JD, Koh M, Song J, Krumholz HM.

BMJ Open. 2019 Mar 23;9(3):e025936. doi: 10.1136/bmjopen-2018-025936.

38.

U.S. prescribing trends of fentanyl, opioids, and other pain medications in outpatient and emergency department visits from 2006 to 2015.

Vijay A, Rhee TG, Ross JS.

Prev Med. 2019 Jun;123:123-129. doi: 10.1016/j.ypmed.2019.03.022. Epub 2019 Mar 17.

PMID:
30894321
39.

Real-Time Targeted Genome Profile Analysis of Pancreatic Ductal Adenocarcinomas Identifies Genetic Alterations That Might Be Targeted With Existing Drugs or Used as Biomarkers.

Singhi AD, George B, Greenbowe JR, Chung J, Suh J, Maitra A, Klempner SJ, Hendifar A, Milind JM, Golan T, Brand RE, Zureikat AH, Roy S, Schrock AB, Miller VA, Ross JS, Ali SM, Bahary N.

Gastroenterology. 2019 Jun;156(8):2242-2253.e4. doi: 10.1053/j.gastro.2019.02.037. Epub 2019 Mar 2.

40.

Communicating, and Justifying, Nonefficacy Benefits for New Drugs Approved on the Basis of Noninferiority Trials.

Ross JS, Wee CC.

JAMA Intern Med. 2019 May 1;179(5):721-722. doi: 10.1001/jamainternmed.2018.8019. No abstract available.

PMID:
30830205
41.

On-target Resistance to the Mutant-Selective EGFR Inhibitor Osimertinib Can Develop in an Allele-Specific Manner Dependent on the Original EGFR-Activating Mutation.

Brown BP, Zhang YK, Westover D, Yan Y, Qiao H, Huang V, Du Z, Smith JA, Ross JS, Miller VA, Ali S, Bazhenova L, Schrock AB, Meiler J, Lovly CM.

Clin Cancer Res. 2019 Jun 1;25(11):3341-3351. doi: 10.1158/1078-0432.CCR-18-3829. Epub 2019 Feb 22.

PMID:
30796031
42.

On the Need for (Only) High-Quality Clinical Practice Guidelines.

Incze M, Ross JS.

JAMA Intern Med. 2019 Apr 1;179(4):561. doi: 10.1001/jamainternmed.2018.7471. No abstract available.

PMID:
30776052
43.

Unique mutation patterns in anaplastic thyroid cancer identified by comprehensive genomic profiling.

Khan SA, Ci B, Xie Y, Gerber DE, Beg MS, Sherman SI, Cabanillas ME, Busaidy NL, Burtness BA, Heilmann AM, Bailey M, Ross JS, Sher DJ, Ali SM.

Head Neck. 2019 Jun;41(6):1928-1934. doi: 10.1002/hed.25634. Epub 2019 Feb 13.

PMID:
30758123
44.

Generic and Brand-Name Thyroid Hormone Drug Use Among Commercially Insured and Medicare Beneficiaries, 2007 Through 2016.

Ross JS, Rohde S, Sangaralingham L, Brito JP, Choi L, Dutcher SK, Graham DJ, Jenkins MR, Lipska KJ, Mendoza M, Qiang Y, Wang Z, Wu Y, Yao X, Shah ND.

J Clin Endocrinol Metab. 2019 Jun 1;104(6):2305-2314. doi: 10.1210/jc.2018-02197.

PMID:
30690529
45.

Hybrid Capture-Based Genomic Profiling Identifies BRAF V600 and Non-V600 Alterations in Melanoma Samples Negative by Prior Testing.

Boussemart L, Nelson A, Wong M, Ross JS, Sosman J, Mehnert J, Daniels G, Kendra K, Ali SM, Miller VA, Schrock AB.

Oncologist. 2019 May;24(5):657-663. doi: 10.1634/theoncologist.2018-0271. Epub 2019 Jan 25.

46.

Genomic Features for Therapeutic Insights of Chemotherapy-Resistant, Primary Mediastinal Nonseminomatous Germ Cell Tumors and Comparison with Gonadal Counterpart.

Necchi A, Bratslavsky G, Chung J, Millis S, Gay LM, Ali SM, Ross JS.

Oncologist. 2019 Apr;24(4):e142-e145. doi: 10.1634/theoncologist.2018-0430. Epub 2019 Jan 18.

PMID:
30659078
47.

Dual Targeting of EGFR and IGF1R in the TNFAIP8 Knockdown Non-Small Cell Lung Cancer Cells.

Day TF, Kallakury BVS, Ross JS, Voronel O, Vaidya S, Sheehan CE, Kasid UN.

Mol Cancer Res. 2019 May;17(5):1207-1219. doi: 10.1158/1541-7786.MCR-18-0731. Epub 2019 Jan 15.

PMID:
30647104
48.

Association of Racial and Socioeconomic Disparities With Outcomes Among Patients Hospitalized With Acute Myocardial Infarction, Heart Failure, and Pneumonia: An Analysis of Within- and Between-Hospital Variation.

Downing NS, Wang C, Gupta A, Wang Y, Nuti SV, Ross JS, Bernheim SM, Lin Z, Normand ST, Krumholz HM.

JAMA Netw Open. 2018 Sep 7;1(5):e182044. doi: 10.1001/jamanetworkopen.2018.2044.

49.

Age of Data at the Time of Publication of Contemporary Clinical Trials.

Welsh J, Lu Y, Dhruva SS, Bikdeli B, Desai NR, Benchetrit L, Zimmerman CO, Mu L, Ross JS, Krumholz HM.

JAMA Netw Open. 2018 Aug 3;1(4):e181065. doi: 10.1001/jamanetworkopen.2018.1065.

50.

Availability of Investigational Medicines Through the US Food and Drug Administration's Expanded Access and Compassionate Use Programs.

Puthumana J, Miller JE, Kim J, Ross JS.

JAMA Netw Open. 2018 Jun 1;1(2):e180283. doi: 10.1001/jamanetworkopen.2018.0283.

Supplemental Content

Support Center